Table 1. Cyfip2 may regulate NMDARs to control acoustic startle sensitivity.
Mean startle index comparisons, listed as percentage (%) of the mean startle index of vehicle-treated controls by cyfip2 genotype and drug concentration, for larvae treated with compounds targeting the indicated pathways [61] to increase acoustic startle sensitivity. All significant differences (p < 0.05) are listed (bold) for comparisons using a Kruskal-Wallis test and Dunn’s multiple comparisons correction. NPAA (N-phenylanthranilic acid); MA (meclofenamic acid); POBA (phenoxybenzamine); ETAZ (etazolate).
| Compound | Concentration (μM) | Effect By Genotype | ||
|---|---|---|---|---|
| cyfip2(+/+) | cyfip2(+/−) | cyfip2(−/−) | ||
| NPAA (Cl-channel antagonist) | 1 | 93.21% of Control, p > 0.99 | 110.21% of Control, p < 0.99 | 113.57% of Control, p > 0.99 |
| 5 | 140.11% of Control, p = 0.9785 | 137.32% of Control, p = 0.1385 | 140.29% of Control, p > 0.2787 | |
| 10 | 234.14% of Control, p** = 0.0038 | 201.29% of Control, p**** < 0.0001 | 155.06% of Control, p* = 0.0189 | |
| MA (K+ channel/gap jxn. antagonist) | 1 | 131.6% of Control, p > 0.99 | 11.87% of Control, p > 0.99 | 132.29% of Control, p = 0.5732 |
| 5 | 137.24% of Control, p > 0.99 | 138.46% of Control, p = 0.0622 | 112.29% of Control, p > 0.99 | |
| 10 | 214.13% of Control, p = 0.0833 | 169.81% of Control, p* = 0.0188 | 155.76% of Control, p* = 0.0288 | |
| POBA (AAR/calmodulin antagonist) | 1 | 102.9% of Control, p > 0.99 | 107.08% of Control, p > 0.99 | 101.04% of Control, p > 0.99 |
| 10 | 136.17% of Control, p > 0.99 | 106.58% of Control, p > 0.99 | 99.01% of Control, p > 0.99 | |
| 50 | 175.8% of Control, p* = 0.0123 | 99.76% of Control, p > 0.99 | ||
| ETAZ (PDE4 inhibitor) | 1 | 141.79% of Control, p > 0.99 | 126.36% of Control, p > 0.99 | 121.74% of Control, p > 0.99 |
| 10 | 168.6% of Control, p = 0.5472 | 172.26% of Control, p* = 0.0137 | 152.73% of Control, p = 0.3977 | |
| 50 | 236.64% of Control, p** = 0.0029 | 179.99% of Control, p** = 0.0015 | 149.75% of Control, p* = 0.0105 | |
| MK-801 (NMDAR antagonist) | 100 | 120.19% of Control, p > 0.99 | 145.93% of Control, p** = 0.0024 | |
| 500 | 212.69% of Control, p**** < 0.0001 | 163.26% of Control, p*** = 0.0002 | ||
| BMS-204352 (K+ channel antagonist) | 10 | 79.48% of Control, p = 0.4269 | 89.55% of Control, p > 0.99 | |
| 50 | 76.08% of Control, p = 0.6759 | 108.74% of Control, p > 0.99 | ||
| NSC-23766 (Rac1 antagonist) |
100 | 49.14% of Control, p*** = 0.0002 | 81.60% of Control, p > 0.99 | |
| 200 | 86.26% of Control, p > 0.99 | 105.28% of Control, p > 0.99 | ||